MUSC Hollings Cancer Center - Report to the Community 2026 - Flipbook - Page 21
A NEW MILESTONE
First TIL
therapy patient
CE LLULA R T HE RA PY
Adult Program
01
TIL TH ERA PY
After years of surgery, immunotherapy, radiation
and targeted therapy, Sally Holcomb was running
out of options to treat her metastatic melanoma.
At Hollings Cancer Center, she found a new
path forward, becoming the center’s 昀椀rst patient
to receive tumor-in昀椀ltrating lymphocyte, or TIL,
therapy. The treatment takes immune cells already
昀椀ghting a patient’s tumor, multiplies them into the
billions and infuses them back into the body to
create a larger cancer-昀椀ghting force.
Bringing the highly specialized therapy to South
Carolina required coordination across dozens of
clinicians and staff and now gives eligible patients
access to the treatment without leaving the state.
For Holcomb, it offered another chance after years
of treatment.
51
A LLOGENEIC
TRA NSPLA NTS
85
68
A U TO L O G OU S
T RA N S P LA N T S
I MM U N E
E F F E CT OR C E L L
T H E RA P IE S
CE LLULA R T HE RA PY
Pediatric Program
16
A LLOGENEIC
TRA NSPLA NTS
08
A UTOLOGOUS
TRA NSPLA NTS
03
I MM U N E
E F F E CT OR C E L L
T H E RA P IE S
“I’m now hopeful about what’s ahead,” she said.
Report to the Community 2026 | 19